Abstract Book

S830

ESTRO 37

failure as well as toxicities after IORT were collected. Statistical analyses was done using Kaplan-Meier analysis and Cox proportional hazards modeling. Results A total of 315 patients who underwent abdominopelvic IORT were included. The median age at IORT was 63 years and median follow-up after IORT was 19.1 months (range, 0.1-407 months). Initial pathology indicated 91.4% of patients had adenocarcinoma whereas 3.5% had squamous cell carcinoma and 5.1% had other histologies. 160 (51%) patients had received previous EBRT, and the median dose was 50.4 Gy in 28 fractions (range, 2500 – 6660 cGy). Median tumor size was 3.5 cm (range, 0.1-13 cm), IORT dose was 15 Gy prescribed to the surface (range, 6 – 36.45 Gy) and applicator size was 5 cm (range, 2 – 5 cm). At last follow-up, 266 (84%) patients were alive. After IORT, 35 (11%) of patients developed a LF and 57 (18%) patients developed metastatic disease. There was no difference in OS based on histology (p=0.14), however, patients with adenocarcinoma histology had a lower risk for developing LF (p=0.03). Risk for LR within the first 24 months was not different between patients based on margin status. Patients with positive margins had a higher risk for developing metastatic disease as well as LR after 24 months (p=0.02). Prior RT (p=0.80), tumor size (p=0.08) or IORT surface dose (p=0.14) were not predictive of local control. Toxicities included ureteral stent placement (11%), wound healing complications (4.1%), hydronephrosis (4.1%), neuropathy (2.2%), and gastrointestinal fistula (1%). Conclusion This series represents one of the largest IORT experiences reported in the literature. We found that the local control with IORT was excellent. Compared to patient with negative margins, patients with positive margins had similar risk for local failure in the first 24 months, however, they had a higher risk for developing distant metastases. Risk for toxicity after IORT was low overall. Our analysis suggests that IORT should be utilized in patients at high risk of having a local recurrence. EP-1536 Quality of Life in cervical cancer patients: A weak relationship exists between PRO and PhRO. R. Ordoñez Marmolejo 1 1 virgen De La Victoria, Oncologia Radioterapica, Málaga, Spain Purpose or Objective To analyze Health-Related Quality of Life (HR-QoL) in cervical cancer patients treated with a curative intent and it relationship with late morbidity and clinical factors. Material and Methods QoL was assessed at a median follow-up of 43 months in 166 patients using European Organization for Research and Treatment of Cancer (EORTC)-C30 (core module), EORTC-Cx24 (cervical module), and Female Sexual Function Index (FSFI, a dimension specific questionnaire on sexual function). A multivariable analysis was performed to clarify prognostic factors that correlate with QoL and late morbidity. Results Patients reported a good or a very good general QoL (scores 72,2± 25,8). Emotional functioning was the most EP-1535 Radiation Therapy for Locoregionally Recurrent Ovarian Cancer Abstract withdrawn

impaired scale (68,2±29,4). The population is sexually low active (38% sexually active) with a score compatible with sexual dysfunction on the FSFI scale (12.5 ± 9.9). Patients engaged in sexual activity showed a higher general QoL (B 12,7), physical functioning (B 11,1) and role functioning (B 14,5), expressed lower symptom experience (B -11,1) and, as expected, it had a positive impact in all the IFSF sub-scales (desire: B 0,9; arousal: B 3,8; lubrication: B 3,6; orgasm: B 4,2; satisfaction: B 1,2; and pain: B 3,9). It was only found a statistically significant relationship between QLQ-C30 general QoL (p=0,006) and QLQ-Cx24 symptom experience (p=0,005) in PRO and the Physician Reported Outcomes (PhRO), measured as maximum late toxicity (worst skin, rectal, bowel, urinary and sexual toxicity during follow up). No association was found between maximum sexual late toxicity and sexual/vaginal functioning, sexual worry, sexual activity and sexual enjoiment (QLQ-Cx24) nor IFSF scales. Conclusion A weak relationship exists between Patient Reported Outcomes and Physician Reported Outcomes. EP-1537 Omission Of Prophylactic Inguinal Irradiation In Stage Iiia Cervical Cancer – Study Of 41 Patients M.A. Dadzie 1 , V. Vanderpuye 1 , F. Asamoah 1 , J. Yarney 1 , N.A. Aryeetey 1 1 Korlebu Teaching Hospital, National Centre for Radiotherapy and Nuclear Medicine, ACCRA, Ghana Purpose or Objective Prophylactic inguinal lymph node irradiation is the current standard of management for stage IIIA cervical cancer to reduce inguinal lymph node recurrence. We present the pattern of recurrence in 41 women with stage IIIA cervical cancer treated with concurrent chemo- radiation with Cobalt -60 teletherapy and brachytherapy without prophylactic inguinal lymph node irradiation. Material and Methods A retrospective study of post treatment recurrence patterns in Stage IIIA cervical cancer cases managed in Accra, Ghana over a 5 year period (2006-2011). Results Seventy two cases of stage IIIA cervical cancer were seen between January 2006 and December 2011. None had clinically positive inguinal lymphadenopathy. Average age was 58years. Majority (95%) had squamous cell carcinoma. 41 (70%)completed concurrent chemo radiation with weekly cisplatin to an average dose of 80Gy to point A. Treatment comprised of external beam radiotherapy with 2-D parallel opposed anterior-posterior fields to pelvis including whole vagina using Cobalt-60 teletherapy and low-dose rate brachytherapy with tandem and ovoids. None received complete prophylactic inguinal lymph node irradiation. After a median follow up of 48months, 8 (19.5%) recurred including 5 (62.5%) distant recurrences and 3 (37.5%) local recurrences. None developed inguinal lymph node recurrence Conclusion Prophylactic complete inguinal lymph node irradiation in cervical cancer patients with lower vaginal involvement (Stage IIIA) may not be indicated in absence of clinically positive inguinal lymphadenopathy. Further research is warranted.